This article is more than 5 years old. Information may no longer be current.

Seven updates in bladder cancer

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

May is Bladder Cancer Awareness Month to promote public awareness programs, increase education and enable the bladder cancer community to get involved.

In conjunction with Bladder Cancer Awareness Month, HemOnc Today presents seven updates in the treatment of urothelial carcinoma that may affect your practice.

• A randomized phase 3 trial that evaluated atezolizumab (Tecentriq, Genentech) — a monoclonal antibody designed to bind with PD-L1 — for treatment of locally advanced or metastatic urothelial cancer failed to meet its primary endpoint. Read more.
• The FDA granted accelerated approval to avelumab (Bavencio, EMD Serono) for the treatment of patients with locally advanced or metastatic urothelial carcinoma, who had disease progression during or following platinum-containing chemotherapy or within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy. Read more.
• Evidence to support the use of adjuvant chemotherapy for patients with upper tract urothelial carcinoma undergoing radical nephroureterectomy is limited, according to Nima Almassi, MD, and Petros Grivas, MD, PhD. Read more.
• The FDA granted accelerated approval to durvalumab (Imfinzi, AstraZeneca) for the treatment of patients with locally advanced or metastatic urothelial carcinoma. The agency also approved the VENTANA PD-L1 Assay (SP263, Ventana Medical Systems) as a complementary diagnostic for the assessment of the PD-L1 protein in formalin-fixed, paraffin-embedded urothelial carcinoma tissue. Read more.
• Adjuvant chemotherapy following radical nephroureterectomy prolonged survival by 1 year compared with observation in patients with upper tract urothelial carcinoma, according to a study published in Journal of Clinical Oncology. Read more.
• The FDA granted accelerated approval to atezolizumab (Tecentriq, Genentech) for the initial treatment of patients with locally advanced or metastatic urothelial carcinoma who are not eligible for cisplatin chemotherapy. Read more.
• Nivolumab (Opdivo, Bristol-Myers Squibb) demonstrated clinical benefit and an acceptable safety profile in previously treated patients with metastatic urothelial carcinoma, according to data from a phase 2 trial. Read more.